Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(19):1422-1424; doi:10.1093/jnci/djg077
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Correction (v95,p1728)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Johnson, B. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, B. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 Oxford University Press

EDITORIAL

Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer: The End of the Beginning

Bruce E. Johnson

Affiliation of author: Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA.

Correspondence to: Bruce E. Johnson, MD, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Rm. D1234, Boston, MA 02445 (e-mail: bejohnson@partners.org).

The first 150 words of the full text of this article appear below.

In this issue of the Journal, Scagliotti and colleagues (1) present results from the Adjuvant Lung Project Italy (ALPI) trial, the largest study yet reported of adjuvant chemotherapy in patients with resected non–small-cell lung cancer (NSCLC). They report that there was no difference in survival between patients who received adjuvant chemotherapy and those who did not. Although patients treated with adjuvant chemotherapy had longer progression-free survival than the untreated patients (hazard ratio = 0.89, 95% confidence interval = 0.76 to 1.03), that finding was not statistically significant. The interpretation of this result is made even more important by the results of two randomized studies (2,3) of adjuvant chemotherapy that were reported at the American Society of Clinical Oncology meeting in 2003. Both studies (2,3) showed a survival advantage for patients with surgically resected early-stage lung cancer who were treated with . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
R. A. Miksad, M. Gonen, T. J. Lynch, and T. G. Roberts Jr
Interpreting Trial Results in Light of Conflicting Evidence: A Bayesian Analysis of Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer
J. Clin. Oncol., May 1, 2009; 27(13): 2245 - 2252.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
L. A. Robinson, J. C. Ruckdeschel, H. Wagner Jr, and C. W. Stevens
Treatment of Non-small Cell Lung Cancer-Stage IIIA: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Chest, September 1, 2007; 132(3_suppl): 243S - 265S.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Gridelli, C. Langer, P. Maione, A. Rossi, and S. E. Schild
Lung Cancer in the Elderly
J. Clin. Oncol., May 10, 2007; 25(14): 1898 - 1907.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Han, N. Sidell, P. B. Fisher, and J. Roman
Up-regulation of p21 Gene Expression by Peroxisome Proliferator-Activated Receptor {gamma} in Human Lung Carcinoma Cells
Clin. Cancer Res., March 15, 2004; 10(6): 1911 - 1919.
[Abstract] [Full Text] [PDF]